Vaxcyte, Inc.
$61.4
▲
1.4%
2026-04-22 10:12:13
vaxcyte.com
NMS: PCVX
Explore Vaxcyte, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.86 B
Current Price
$61.4
52W High / Low
$65 / $28.09
Stock P/E
—
Book Value
$20.49
Dividend Yield
—
ROCE
-33.02%
ROE
-25.59%
Face Value
—
EPS
$-5.63
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
507
Beta
1.39
Debt / Equity
4.38
Current Ratio
7.91
Quick Ratio
7.91
Forward P/E
-8.35
Price / Sales
—
Enterprise Value
$7.32 B
EV / EBITDA
-8.07
EV / Revenue
—
Rating
Strong Buy
Target Price
$109
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Dyadic International, Inc. | $0.88 | — | $31.88 M | — | -114.18% | -3.98% | $1.35 / $0.65 | $0.03 |
| 2. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 3. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
| 4. | Sol-Gel Technologies Ltd. | $70 | — | $228.83 M | — | -31.74% | -23.72% | $97.97 / $4.11 | $8.19 |
| 5. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
| 6. | Sionna Therapeutics, Inc. | $42.64 | — | $1.96 B | — | -28.32% | -31.79% | $46.46 / $9.24 | $6.86 |
| 7. | Disc Medicine, Inc. | $71.41 | — | $2.74 B | — | -30.64% | -35.86% | $99.5 / $39.2 | $19.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -274.28 M | -242.38 M | -226.22 M | -180.79 M | -162.98 M | — |
| Net Profit | -246.51 M | -212.83 M | -166.57 M | -140.72 M | -137.08 M | — |
| EPS in Rs | -1.71 | -1.48 | -1.16 | -0.98 | -0.95 | -0.83 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -923.67 M | -569.55 M | -393.04 M | -209.26 M |
| Net Profit | -766.63 M | -463.93 M | -402.27 M | -223.49 M |
| EPS in Rs | -5.33 | -3.22 | -2.8 | -1.55 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3 B | 3.51 B | 1.41 B | 1.01 B |
| Total Liabilities | 317.21 M | 205.5 M | 167.45 M | 52.56 M |
| Equity | 2.69 B | 3.31 B | 1.24 B | 953.61 M |
| Current Assets | 1.63 B | 1.79 B | 1.1 B | 942.55 M |
| Current Liabilities | 205.75 M | 140.18 M | 145.34 M | 40.52 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -655.58 M | -452.63 M | -296.79 M | -170.6 M |
| Investing CF | 437.35 M | -2.01 B | -773.31 M | 74.58 M |
| Financing CF | 2.01 M | 2.45 B | 639.81 M | 861.55 M |
| Free CF | -712.55 M | -571.79 M | -364.67 M | -176.44 M |
| Capex | -56.97 M | -119.16 M | -67.88 M | -5.84 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -15.33% | -80% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.